Aug 2026· The Journal of Cardiovascular Aging· Vol 6· 0 citations· 44 references
TL;DR
It is suggested that CARD10 deficiency is associated with enhanced fibroblast senescence and improved post-MI remodeling, potentially involving mitochondrial dysfunction and PI3K/AKT signaling, highlighting CARD10 may represent a promising target for the treatment of MI.
Abstract
Aim: Myocardial infarction (MI) causes cardiomyocyte death and triggers tissue repair and remodeling processes orchestrated by multiple cell types, particularly cardiac fibroblasts (CFs). Caspase recruitment domain-containing protein 10 (CARD10) has been implicated in mitochondrial function and aneurysm formation; however, its role in MI is not clear. To investigate the potential role of CARD10 in MI and the underlying mechanisms.
Methods: CARD10 expression and localization were analyzed by Western blot and immunofluorescence in mouse and human heart tissues. CARD10-deficient (Card10-/- ) and wild-type (WT) mice were subjected to experimental MI. Cardiac structure and function were assessed by echocardiography, histological analysis, and triphenyltetrazolium chloride (TTC). Cellular senescence was evaluated in vivo and in primary CFs using senescence-associated β-galactosidase (SA-β-gal) staining and the expression of p16 and phosphorylated histone H2A.X (gH2A.X). Mitochondrial dysfunction was assessed by JC-1 staining, mitochondrial reactive oxidative species (mtROS) measurements, and transmission electron microscopy. Potential signaling pathways were investigated by Western blot analysis.
Results: Following MI, CARD10 expression was increased in the infarct border zone and was predominantly localized with CFs. Card10 -/- attenuated myocardial injury, improved cardiac remodeling, and enhanced fibroblast senescence. In vitro, transforming growth factor-beta (TGF-β)-stimulated Card10-/- CFs exhibited increased senescence, accompanied by elevated secretion of senescence-associated secretory phenotype (SASP) factors. Conditioned media from Card10-/- CFs promoted endothelial cell proliferation and angiogenesis. Furthermore, Card10-/- CFs exhibited severe mitochondrial dysfunction and activation of the phosphoinositide 3-kinase (PI3K) /protein kinase B (AKT) signaling pathway.
Conclusion : These findings suggest that CARD10 deficiency is associated with enhanced fibroblast senescence and improved post-MI remodeling, potentially involving mitochondrial dysfunction and PI3K/AKT signaling, highlighting CARD10 may represent a promising target for the treatment of MI.
Myocardial fibrosis is a common pathological feature that affects the outcome of various heart diseases, typically in the context of myocardial infarction (MI). The role of T cells in heart failure has been increasingly recognized, but whether programmed cell death protein 1 (PD1+) T cells modulate cardiac fibrosis dur...
Xiao-Ying Chen, Chang-Chen Xiao, Chang-Le Ke et al.· Cell Discovery· 0 citations
OBJECTIVE
To investigate when and how activating transcription factor 6 (ATF6) contributes to macrophages (Mφ) polarization and tissue repair after myocardial ischemia/reperfusion (I/R) injury.
METHODS
The WT and ATF6 knockout (ATF6-/-) mice were subjected to myocardial I/R injury. Endoplasmic reticulum stress (ERS)...
Zi-Min Wu, Si-Si Mo, Zu-Yuan Huang et al.· Metabolism: Clinical and Exp...· 0 citations
Background: Endothelial defects in the heart are a contributor to cardiac pathological remodeling and dysfunction, which can be influenced by cardiomyocytes (CMs). Here, we explore cardioprotective crosstalk between CMs and endothelial cells (ECs) under diabetic conditions. Methods: Type 2 diabetes mellitus (T2DM) was...
S. Gare, N. H. Alatawi, Xin-Yi Chen et al.· Circulation Research· 0 citations
It is demonstrated that BRCC3 protects against ischemic injury and pathological remodeling by deubiquitinating Smad3 at K333 to antagonize TGF-β1/Smad3 signaling, identifying BRCC3 as a potential therapeutic target for preventing post-AMI heart failure.
De-Shan Yao, Si-Chuan Wang, Ru-Jun Li et al.· Research· 0 citations
ERIO is a safe, effective natural flavonoid with promising preclinical efficacy, suggesting its potential clinical translation for myocardial fibrosis and offering new therapeutic targets to prevent heart failure progression.
Yu-Ting Liu, Yan Che, Yazhi Ding et al.· British Journal of Pharmacol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.